DrugPatentWatch Database Preview
Patent: 8,415,382
» See Plans and Pricing
Summary for Patent: 8,415,382
| Title: | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase |
| Abstract: | New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer. |
| Inventor(s): | Costales; Abran (El Cerrito, CA), Hansen; Teresa (Danville, CA), Levine; Barry H. (Lafayette, CA), McBride; Christopher (Oakland, CA), Poon; Daniel J. (Oakland, CA), Ramurthy; Savithri (Walnut Creek, CA), Renhowe; Paul A. (Danville, CA), Shafer; Cynthia M. (El Sobrante, CA), Subramanian; Sharadha (San Ramon, CA), Verhagen; Joelle (Richmond, CA) |
| Assignee: | Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) |
| Application Number: | 12/205,028 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,415,382
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) | 2039-02-26 | RX | search | |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) | 2039-02-26 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) | 2039-02-26 | RX | Orphan | search |
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | Start Trial | Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) | 2039-02-26 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,415,382
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2005037273 | Start Trial |
| United States of America | 2005192287 | Start Trial |
| United States of America | 2009035309 | Start Trial |
| United States of America | 2013224195 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
